Agios stops blood cancer drug program after trial
Agios Pharmaceuticals will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after a mid-stage trial failed to meet efficacy goals. The company plans to continue testing the drug for sickle cell disease with results expected in late 2026.
Xurve View
Insights:
Xurve View
AGIOS PHARMACEUTICALS INC will stop developing tebapivat for blood cancer after a mid-stage trial failed to meet efficacy goals. Shares fell 1.7% in the United States during morning trading following the announcement. The failure narrows the pipeline for the rare-disease specialist as it pivots toward sickle cell treatments.
